Want to see CLBT full AI Analyst Report?
Top Page
Cellebrite DI
(NASDAQ:CLBT)
Select Model
Select Model
Rating:78Outperform
Price Target:
$19.00
▲(44.16% Upside)
Action:Reiterated
Date:06/02/26
The score is driven primarily by strong financial quality (high margins, robust free cash flow, low leverage) and a positive earnings-call setup (guidance for ARR acceleration plus strategic catalysts like AI products and FedRAMP). Offsetting factors are a rich valuation (P/E ~54) and technical indicators that are strong but near overbought, alongside the fundamental risk of slowing recent revenue growth versus prior periods.
Positive Factors
Margin & Cash Generation
Sustained high gross margins and strong trailing‑12‑month free cash flow provide durable operating leverage and self‑funding for product R&D, go‑to‑market and M&A. This cash generation underpins resilience through cycles, supports reinvestment and reduces reliance on external financing.
Negative Factors
Slowing Revenue Growth
A marked deceleration in top‑line growth weakens the base case for multi‑year momentum and raises reliance on product launches and cross‑sell to restore growth. Persistent slower growth pressures operating leverage and makes execution on new offerings essential to sustain ARR and margins.
Read all positive and negative factors
Positive Factors
Negative Factors
Margin & Cash Generation
Sustained high gross margins and strong trailing‑12‑month free cash flow provide durable operating leverage and self‑funding for product R&D, go‑to‑market and M&A. This cash generation underpins resilience through cycles, supports reinvestment and reduces reliance on external financing.
Read all positive factors
Cellebrite DI Key Performance Indicators (KPIs)
Any
Revenue by Geography
Maps where sales are coming from across regions, indicating dependence on particular markets, exposure to geopolitical or regulatory risk, and where expansion or slowdown might materially affect overall growth.
Maps where sales are coming from across regions, indicating dependence on particular markets, exposure to geopolitical or regulatory risk, and where expansion or slowdown might materially affect overall growth.
Data provided by:
The Fly
The FlyCellebrite DI (CLBT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.14B
Dividend YieldN/A
Average Volume (3M)2.19M
Price to Earnings (P/E)56.7
Beta (1Y)0.76
Revenue Growth18.43%
EPS GrowthN/A
CountryUS
Employees1,167
SectorTechnology
Sector Strength88
IndustrySoftware - Infrastructure
Share Statistics
EPS (TTM)0.29
Shares Outstanding249,439,820
10 Day Avg. Volume2,219,652
30 Day Avg. Volume2,187,737
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)9.41
Price to Sales (P/S)9.58
P/FCF Ratio29.25
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue6.04
Enterprise Value/Gross Profit7.21
Enterprise Value/Ebitda23.50
Forecast
1Y Price Target
$19.75Price Target Upside49.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.37
Revenue Forecast (FY)$567.97M
Cellebrite DI Business Overview & Revenue Model
Company Description
Cellebrite DI Ltd. delivers specialized digital intelligence solutions crafted for legally authorized investigations. Their comprehensive DI platform enables users to efficiently gather, scrutinize, interpret, and oversee digital information throu...
How the Company Makes Money
Cellebrite makes money primarily by selling subscriptions and licenses to its digital intelligence software and platforms, along with associated maintenance/support and professional services. Key revenue streams generally include: (1) Software/pla...
Cellebrite DI Earnings Call Summary
Earnings Call Date:May 14, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call featured multiple strong financial and strategic highlights: ARR growth of 21% to $493M, revenue +19% to $128.3M, adjusted EBITDA +29% and robust free cash flow. Management delivered major product milestones (Genesis AI, Guardian Investigate), FedRAMP High authorization, improving regional momentum (U.S. Fed pipeline +35%, EMEA growth at 25%), and optimistic Q2 guidance that implies meaningful sequential acceleration. Lowlights were primarily execution and timing risks (seasonal Q1 softness, deal push-outs, acquisition-related costs), a modest near-term net-new ARR cadence, FX headwinds (~2 points) and the need to convert strong early AI adoption into paying customers. Overall the positives—especially the combination of strong financials, rapid AI adoption, large estimated AI TAM and strategic certifications—outweigh the transitory negatives, though execution will be important to sustain the opportunity.Positive Updates
ARR Growth
ARR increased 21% year-over-year to $493 million in Q1 2026, with sequential ARR growth of $12 million and management reaffirming full-year guidance.
Negative Updates
Q1 ARR Net-New Pace and Seasonality
Q1 net new ARR was modest (Q1 is historically the most difficult quarter), with some deal timing and push-outs cited; management noted an unusually small pool of contract expirations which weighed on net-new ARR in the quarter.
Read all updates
Q1-2026 Updates
Positive
Negative
ARR Growth
ARR increased 21% year-over-year to $493 million in Q1 2026, with sequential ARR growth of $12 million and management reaffirming full-year guidance.
Read all positive updates
Company Guidance
Cellebrite reiterated its full‑year 2026 thesis and gave Q2 guidance: following Q1 ARR of $493M (+21% YoY) and adjusted EBITDA of $30.6M (+29%), management expects Q2 ARR of $510–513M (net new ARR $17–20M, roughly 50% sequential growth at the midpoint), Q2 revenue of $130–133M (+15–17% YoY), and Q2 adjusted EBITDA of $29–31M (margin 22–23%), factoring in an estimated ~2‑point FX headwind; they also highlighted strong cash and profitability metrics (cash, equivalents & investments ≈ $535M; TTM free cash flow $159M with a 32% FCF margin; adjusted EBITDA margin 23.9% in Q1), reiterated that growth products should comprise ~20% of ARR by year‑end, and noted upside to prior plans from AI (Genesis) with a multi‑year Investigative AI TAM estimated at ~$12.5B.Cellebrite DI Financial Statement Overview
Summary
Income Statement
77
Positive
Balance Sheet
88
Very Positive
Cash Flow
83
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 496.43M | 475.68M | 401.20M | 325.11M | 270.65M | 246.25M |
| Gross Profit | 416.32M | 400.50M | 338.61M | 271.88M | 219.91M | 203.69M |
| EBITDA | 127.62M | 103.07M | -265.35M | -65.41M | 130.10M | 89.47M |
| Net Income | 71.86M | 78.33M | -283.01M | -81.10M | 120.81M | 71.40M |
Balance Sheet | ||||||
| Total Assets | 952.29M | 938.85M | 690.57M | 532.88M | 403.29M | 339.78M |
| Cash, Cash Equivalents and Short-Term Investments | 429.07M | 437.05M | 447.22M | 302.92M | 183.62M | 181.56M |
| Total Debt | 22.80M | 22.67M | 10.97M | 14.13M | 15.36M | 0.00 |
| Total Liabilities | 441.75M | 454.53M | 354.55M | 498.67M | 329.43M | 413.13M |
| Stockholders Equity | 510.54M | 484.32M | 336.02M | 34.21M | 73.86M | -73.35M |
Cash Flow | ||||||
| Free Cash Flow | 154.04M | 155.73M | 121.56M | 94.14M | 11.49M | 27.94M |
| Operating Cash Flow | 167.97M | 168.96M | 132.17M | 102.06M | 20.58M | 36.05M |
| Investing Cash Flow | -155.32M | -268.25M | -149.47M | -22.54M | -91.23M | 45.23M |
| Financing Cash Flow | 29.53M | 29.64M | 20.65M | 21.77M | 13.97M | -68.40M |
Cellebrite DI Technical Analysis
Positive
13.18
Price Trends
13.52
Positive
13.62
Positive
15.58
Positive
Market Momentum
0.68
Negative
73.41
Negative
93.44
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLBT, the sentiment is Positive. The current price of 13.18 is below the 20-day moving average (MA) of 13.68, below the 50-day MA of 13.52, and below the 200-day MA of 15.58, indicating a bullish trend. The MACD of 0.68 indicates Negative momentum. The RSI at 73.41 is Negative, neither overbought nor oversold. The STOCH value of 93.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLBT.
Cellebrite DI Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $4.14B | 56.73 | 15.53% | ― | 18.43% | ― | |
75 Outperform | $4.55B | -426.68 | -3.71% | ― | 10.74% | 74.22% | |
75 Outperform | $1.26B | 19.10 | 6.22% | 4.71% | 5.43% | 208.11% | |
73 Outperform | $1.31B | 67.52 | 5.71% | ― | 9.83% | 65.00% | |
62 Neutral | $1.77B | 13.32 | 20.68% | 0.68% | 9.44% | 3.45% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
60 Neutral | $5.24B | -40.57 | -26.10% | ― | 15.27% | -39.93% |
* Technology Sector Average
CLBT
Cellebrite DI
16.57
1.22
7.95%
RDWR
Radware
30.49
-0.07
-0.23%
EVTC
Evertec
28.60
-7.30
-20.33%
VRNS
Varonis Systems
45.84
-7.72
-14.42%
TENB
Tenable Holdings
40.62
5.16
14.55%
TUYA
Tuya
1.96
-0.45
-18.77%
Cellebrite DI Corporate Events
Cellebrite Posts Strong Q1 2026 Growth, Expands AI and Drone Forensics Portfolio
May 14, 2026
On May 14, 2026, Cellebrite reported first-quarter 2026 results showing revenue of $128.3 million, up 19% year over year, with subscription revenue rising 23% to $117.9 million and annual recurring revenue climbing 21% to $493 million. The company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.